August 22, 2025Open Access

CXCL12, SCF, and eotaxin are prognostic serum biomarkers in gastric cancer

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Analysis identifies CXCL12 and eotaxin as significant prognostic biomarkers in gastric cancer patients, suggesting new clinical insights.

CXCL12 and eotaxin independently predict disease-specific survival in gastric cancer patients, enhancing prognostic accuracy.
Among 48 biomarkers studied, CXCL12 had a hazard ratio of 0.39 and eotaxin a hazard ratio of 0.57, indicating significant survival implications.
Observational analysis of serum biomarkers identified key cytokines influencing cancer prognosis in patients with gastric adenocarcinoma.
Findings suggest that inflammatory serum biomarkers could inform clinical decisions and improve understanding of gastric cancer outcomes.

Brodkin et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark